The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Open accessAbstract
BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is associated with natalizumab treatment. We quantified the risk of PML in patients with multiple sclerosis, according to the presence or absence of three risk factors: positive status with respect to anti-JC virus antibodies, prior use of immunosuppressants, and increasing duration of natalizumab treatment. METHODS: We used data from postmarketing sources, clinical studies, and an independent Swedish registry to estimate the incidence of PML among natalizumab-treated patients with multiple sclerosis, according to positive or negative status with respect to anti-JC virus antibodies, prior or no prior use of immunosuppressants, and duration of treatment (1 to 24 months vs. 25 to 48 months). Blood samples were available for anti-JC virus antibody testing from 5896 patients with multiple sclerosis and from 54 patients with multiple sclerosis who were treated with natalizumab and in whom PML later developed. RESULTS: As of February 29, 2012, there were 212 confirmed cases of PML among 99,571 patients treated with natalizumab (2.1 cases per 1000 patients). All 54 patients with PML for whom samples were available before the diagnosis were positive for anti-JC virus antibodies. When the risk of PML was stratified according to three risk factors, the risk of PML was lowest among the patients who were negative for anti-JC virus antibodies, with the incidence estimated to be 0.09 cases or less per 1000 patients (95% confidence interval [CI], 0 to 0.48). Patients who were positive for anti-JC virus antibodies, had taken immunosuppressants before the initiation of natalizumab therapy, and had received 25 to 48 months of natalizumab treatment had the highest estimated risk (incidence, 11.1 cases per 1000 patients [95% CI, 8.3 to 14.5]). CONCLUSIONS: Positive status with respect to anti-JC virus antibodies, prior use of immunosuppressants, and increased duration of natalizumab treatment, alone or in combination, were associated with distinct levels of PML risk in natalizumab-treated patients with multiple sclerosis. (Funded by Biogen Idec and Elan Pharmaceuticals.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Self-citationKleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054693 · Cited by 790
Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors
Egli, A., Infanti, L., Dumoulin, A., Buser, A., Samaridis, J., Stebler, C., Gosert, R., & Hirsch, H. H. (2009) · The Journal of Infectious Diseases · doi:10.1086/597126 · Cited by 781
Tan, C. S., & Koralnik, I. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70040-5 · Cited by 776
Clifford, D. B., DeLuca, A., Simpson, D. M., Arendt, G., Giovannoni, G., & Nath, A. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70028-4 · Cited by 636
Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies
Major, E. O. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080708.082655 · Cited by 437
Anti‐JC virus antibodies: Implications for PML Risk Stratification
Gorelik, L., Lerner, M., Bixler, S., Crossman, M., Schlain, B., Simon, K., Pace, A., Cheung, A., Chen, L. L., Berman, M., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22128 · Cited by 433
Self-citation
Research works printed but not linked: 8
- Gorelik L, 2010, Mult Scler J, 16, S306
- Olsson T, 2010, Mult Scler J, 16, S348
- Subramanyam M, 2010, Mult Scler J, 16, S38
- 10.1212/WNL.0b013e31821a446b · doi:10.1212/wnl.0b013e31821a446b
- 10.1007/s00115-011-3319-2 · doi:10.1007/s00115-011-3319-2
- Butzkueven H, 2011, Mult Scler J, 17, S519
- Bozic C, 2011, Mult Scler J, 17, S355
- Olsson T, 2011, Mult Scler J, 17, S134
Cited by
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Self-citationThompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30481-1 · Cited by 1,797
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2018.27 · Cited by 1,421
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
Diagnosis and Treatment of Multiple Sclerosis: A Review
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021) · JAMA · doi:10.1001/jama.2020.26858 · Cited by 1,205
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Colombel, J.-F., Sands, B. E., Rutgeerts, P., Sandborn, W., Danese, S., D'Haens, G., Panaccione, R., Loftus, E. V., Sankoh, S., Fox, I., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311079 · Cited by 806
Sands, B. E., Feagan, B. G., Rutgeerts, P., Colombel, J.-F., Sandborn, W. J., Sy, R., D’Haens, G., Ben-Horin, S., Xu, J., Rosario, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.05.008 · Cited by 715
Immunological pathogenesis of inflammatory bowel disease
Lee, S. H., Kwon, J. E., & Cho, M.-L. (2018) · Intestinal Research · doi:10.5217/ir.2018.16.1.26 · Cited by 575
Self-citationon behalf of the MAGNIMS study group (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.157 · Cited by 473
Plavina, T., Subramanyam, M., Bloomgren, G., Richman, S., Pace, A., Lee, S., Schlain, B., Campagnolo, D., Belachew, S., & Ticho, B. (2014) · Annals of Neurology · doi:10.1002/ana.24286 · Cited by 438
Self-citationMultiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Wingerchuk, D. M., & Carter, J. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.002 · Cited by 416
Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease
Cortese, I., Reich, D. S., & Nath, A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00427-y · Cited by 387
Immune interventions in stroke
Fu, Y., Liu, Q., Anrather, J., & Shi, F.-D. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.144 · Cited by 383
Baker, K. F., & Isaacs, J. D. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211555 · Cited by 370
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
Garg, N., & Smith, T. W. (2015) · Brain and Behavior · doi:10.1002/brb3.362 · Cited by 348
Traboulsee, A., Simon, J. H., Stone, L., Fisher, E., Jones, D. E., Malhotra, A., Newsome, S. D., Oh, J., Reich, D. S., Richert, N., et al. (2016) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4539 · Cited by 340
Multiple sclerosis—a quiet revolution
Ransohoff, R. M., Hafler, D. A., & Lucchinetti, C. F. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.14 · Cited by 338
Immunology of Relapse and Remission in Multiple Sclerosis
Steinman, L. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120227 · Cited by 330
Ho, P.-R., Koendgen, H., Campbell, N., Haddock, B., Richman, S., & Chang, I. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30282-x · Cited by 320
Self-citationLeukocyte Trafficking to the Small Intestine and Colon
Habtezion, A., Nguyen, L. P., Hadeiba, H., & Butcher, E. C. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.10.046 · Cited by 315
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Rotstein, D., & Montalban, X. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0170-8 · Cited by 289
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
Wyant, T., Fedyk, E., & Abhyankar, B. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw092 · Cited by 284
Inflammatory responses in hypoxic ischemic encephalopathy
Liu, F., & Mccullough, L. D. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.89 · Cited by 283
Mitroulis, I., Alexaki, V. I., Kourtzelis, I., Ziogas, A., Hajishengallis, G., & Chavakis, T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.008 · Cited by 283
Disease‐modifying treatments for multiple sclerosis – a review of approved medications
Torkildsen, Ø., Myhr, K. ‐., & Bø, L. (2016) · European Journal of Neurology · doi:10.1111/ene.12883 · Cited by 280
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings
Coles, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H.-P., Havrdova, E., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004354 · Cited by 277
Body fluid biomarkers in multiple sclerosis
Comabella, M., & Montalban, X. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70233-3 · Cited by 258
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Gajofatto, A., & Benedetti, M. D. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i7.545 · Cited by 256
Disease-modifying therapies and infectious risks in multiple sclerosis
Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H.-P., & Zettl, U. K. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.21 · Cited by 254
Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
Havrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H.-P., Fox, E. J., Giovannoni, G., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004313 · Cited by 221
Understanding the Role of T Cells in CNS Homeostasis
Ellwardt, E., Walsh, J. T., Kipnis, J., & Zipp, F. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.12.008 · Cited by 156
Body fluid biomarkers for multiple sclerosis—the long road to clinical application
Teunissen, C. E., Malekzadeh, A., Leurs, C., Bridel, C., & Killestein, J. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.173 · Cited by 106
Blood Neurofilament Light Chain: The Neurologist’s Troponin?
Thebault, S., Booth, R. A., & Freedman, M. S. (2020) · Biomedicines · doi:10.3390/biomedicines8110523 · Cited by 101
Bruton’s tyrosine kinase inhibition in multiple sclerosis
Schneider, R., & Oh, J. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01229-z · Cited by 47
Estin, M. L., Thompson, S. B., Traxinger, B., Fisher, M. H., Friedman, R. S., & Jacobelli, J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701886114 · Cited by 45
“However, use of natalizumab is limited in patients who are infected with the JC Virus, as they are at risk for progressive multifocal leukoencephalopathy, a fatal complication (69, 70).”
BackgroundMolecular diagnostics in cerebrospinal fluid for the diagnosis of central nervous system infections
Olie, S. E., Andersen, C. Ø., van de Beek, D., & Brouwer, M. C. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00021-24 · Cited by 38
“PML due to JC virus activation is most common in HIV patients or patients that are treated with certain immunosuppressive drugs, most commonly the monoclonal antibody natalizumab (248).”
Davé, V. A., & Klein, R. S. (2023) · Glia · doi:10.1002/glia.24294 · Cited by 29
“…through the BBB is essential for viral control and prevention of serious encephalopathies, as indicated by the associa- tion between Natulizumab blocking leukocyte extravasation into the brain and risk of serious opportunistic CNS infections by human poly- omavirus 2 (Bloomgren et al., 2012).”
BackgroundRocha, A. J. D., Littig, I. A., Nunes, R. H., & Tilbery, C. P. (2013) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20130162 · Cited by 28
Metadata
- Authors
- Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J. V., Sandrock, A., & Bozic, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-05-17
- Volume
- 366
- Issue
- 20
- Pages
- 1870-1880
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2044022462
- Cited by
- 1,242
- References
- 11
- FWCI
- 72.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.